Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

CvLPRIT: Long-term Reduction in Death/MI With Complete Revascularization

Michael O'Riordan

December 20, 2019

News Daily News

Repeat Target-Lesion PCI: An Option for Public Reporting?

Michael O'Riordan

October 25, 2019

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

L.A. McKeown

October 02, 2019

News Daily News

PET May Be Able to Pinpoint PAD Patients at Risk of Restenosis

Caitlin E. Cox

August 15, 2019

News Daily News

CT Perfusion Imaging for In-Stent Restenosis Shows Promise

Yael L. Maxwell

August 15, 2019

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

L.A. McKeown

June 10, 2019

News Daily News

Staged, Complete PCI Beats Culprit Stenting Out to 5 Years in STEMI Patients

Caitlin E. Cox

May 10, 2019

News Daily News

Three Years On, Absorb BVS Still Doesn’t Improve Myocardial Blood Flow

Michael O'Riordan

April 30, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for March 2019

Shelley Wood

March 29, 2019

News Daily News

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

L.A. McKeown

March 15, 2019

News Daily News

The Case for Collateralization: CABG’s Mechanism for Survival in Stable CAD Underappreciated by Patients

L.A. McKeown

February 26, 2019

News Daily News

NOTION and UK TAVI Report Good Long-term Function of Transcatheter Aortic Valves

L.A. McKeown

February 06, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Slight Advantage for DES Over DCB for In-Stent Restenosis: Updated Meta-analysis

Todd Neale

January 15, 2019

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

Advertisement

CvLPRIT: Long-term Reduction in Death/MI With Complete Revascularization

Repeat Target-Lesion PCI: An Option for Public Reporting?

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

PET May Be Able to Pinpoint PAD Patients at Risk of Restenosis

CT Perfusion Imaging for In-Stent Restenosis Shows Promise

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

Staged, Complete PCI Beats Culprit Stenting Out to 5 Years in STEMI Patients

Three Years On, Absorb BVS Still Doesn’t Improve Myocardial Blood Flow

TCTMD’s Top 10 Most Popular Stories for March 2019

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

The Case for Collateralization: CABG’s Mechanism for Survival in Stable CAD Underappreciated by Patients

NOTION and UK TAVI Report Good Long-term Function of Transcatheter Aortic Valves

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Slight Advantage for DES Over DCB for In-Stent Restenosis: Updated Meta-analysis

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content